The EGFR tyrosine kinase inhibitor gefitinib (Iressa) should be considered a first-line treatment option for nonsmoking Asian patients with adenocarcinoma of the lung, according to results from the large Iressa Pan-Asia Study (IPASS) conducted at the Chinese University of Hong Kong.